Bayer
€44.94Change from previous close: −1.01%Absolute change: −€0.46
At a glance
- Revenue growth
- −2.21%
- 2025 vs 2024
- Net margin
- -7.9%
- 2024: -5.5%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 690 | -1,794 | 4,202 | 1,685 | 1,058 | -1,015 | 4,997 | 2,111 | 2,410 | -2,150 | 5,607 | 2,576 |
| Depreciation and amortization | 1,158 | 1,233 | 1,738 | 955 | 272 | 1,148 | 926 | 944 | 1,021 | 1,087 | -5,052 | 905 |
| Capital expenditure | -660 | -411 | -798 | -836 | -465 | -388 | -1,099 | -605 | -628 | -446 | -996 | -683 |
| Investing cash flow | -707 | 280 | -518 | -1,067 | 154 | 161 | -1,294 | 3,758 | -2,603 | 303 | -3,884 | -138 |
| Financing cash flow | -1,477 | 528 | -2,891 | 730 | -482 | -1,241 | -2,109 | -5,054 | -692 | 677 | -2,453 | -160 |
| Dividends paid | -112 | — | -11.0 | -8.0 | -108 | — | — | -5.0 | -108 | — | — | -4.0 |
| Share repurchases | — | — | -14.0 | — | — | — | -16.0 | — | — | — | -24.0 | — |
| Debt issued | 1,944 | 1,243 | 347 | 3,440 | 1,554 | 941 | 1,212 | 1,673 | 1,371 | 1,559 | 6,121 | 4,227 |
| Debt repaid | -2,840 | -513 | -2,619 | -2,344 | -1,399 | -1,965 | -2,624 | -6,201 | -1,316 | -692 | -8,005 | -3,960 |
| Effect of exchange rates | 48.0 | 56.0 | -14.0 | -8.0 | -186 | -79.0 | 38.0 | -84.0 | 48.0 | -12.0 | -179 | 56.0 |
| Net change in cash | -1,439 | -943 | 774 | 1,340 | 542 | -2,176 | 1,572 | 731 | -837 | -1,182 | -908 | 2,334 |
| Free cash flow | 30.0 | -2,205 | 3,404 | 849 | 593 | -1,403 | 3,898 | 1,506 | 1,782 | -2,596 | 4,611 | 1,893 |
| Levered free cash flow | 897 | -2,437 | 8,519 | 1,031 | 1,046 | -1,219 | 5,126 | -826 | 2,110 | -2,235 | 2,353 | -850 |